M. Bader

Developability assessment during the selection of novel therapeutic antibodies.

H. Kettenberger, J. Regula, A. Papadimitriou, 2015, Journal of pharmaceutical sciences.

Phase I trial of 9-cis retinoic acid in adults with solid tumors.

S. Lippman, J. Kurie, W. Hong, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Combined Inhibition of Tumor Necrosis Factor α and Interleukin‐17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody

Seng-Lai Tan, A. Tissot, G. Schett, 2015, Arthritis & rheumatology.

Combined inhibition of TNFα and IL-17 as therapeutic opportunity for treatment in rheumatoid arthritis: Development and characterization of a novel bispecific antibody

A. Tissot, G. Schett, Johannes Auer, 2014 .

Sequential methotrexate, 5-fluorouracil (high-dose), and doxorubicin for advanced gastric cancer.

M. Bader, C. Blajman, A. Marantz, 1986, Cancer treatment reports.

End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations

M. Bader, T. Schlothauer, K. Bray-French, 2023, International journal of pharmaceutics: X.

Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85).

M. Bader, C. Albera, A. Romero, 1997, British Journal of Cancer.

Developability assessment during the selection of novel therapeutic antibodies.

H. Kettenberger, J. Regula, A. Papadimitriou, 2015, Journal of pharmaceutical sciences.